INTRODUCTION {#s1}
============

Liver cancer is the second and sixth leading cause of cancer-related deaths worldwide among men and women, respectively \[[@R1]\]. Approximately 70% to 90% of primary liver malignancies are hepatocellular carcinoma (HCC) \[[@R2], [@R3]\]. A diagnosis of HCC is often made in patients with intermediate- to late-stage disease due to the mild, nonspecific symptoms associated with HCC onset \[[@R4]\], resulting in poor prognosis in most cases \[[@R3]\]. Therefore, radiotherapy and chemotherapy may be more effective than curative surgery for treating late-stage disease due to the invasive nature of HCC \[[@R5]\]. The combination of these factors make HCC a serious public health problem, especially in Eastern and Southeastern Asia \[[@R1]\].

Transcatheter arterial chemoembolization (TACE), which is used to temporarily block blood flow to tumor sites, has been shown to be effective for the treatment of HCC patients who are not candidates for surgical resection, and often causes fewer side effects than conventional systemic chemotherapy methods \[[@R6], [@R7]\]. However, the localized ischemia and hypoxia brought about during TACE treatment can activate tumorigenic VEGF, IGF-2, and bFGF signaling pathways in some tumors, which can subsequently stimulate angiogenesis and the growth of residual tumor cells, leading to tumor recurrence and metastasis \[[@R8], [@R9]\]. Therefore, the suppression of these precancer pathways during TACE treatment for HCC might improve clinical outcomes.

Sorafenib has been shown to suppress tumor growth and inhibit angiogenesis by inhibiting Raf kinase and receptor tyrosine kinases \[[@R10], [@R11]\], and has demonstrated relatively good therapeutic effects for the treatment of HCC \[[@R11], [@R12]\]. In recent years, researchers have evaluated TACE combined with sorafenib in the treatment of HCC, but the findings of clinical studies have been inconsistent, especially with regard to whether TACE combined with sorafenib \[[@R13], [@R14]\]. Two recent meta-analyses showed that TACE with sorafenib for HCC improved time to disease progression (TTP), but did not improve overall survival (OS), compared with that of TACE alone. However, 3 of the 5 studies included in those meta-analyses were not RCTs \[[@R13]--[@R17]\].

A meta-analysis is therefore needed to clarify the results of randomized controlled trials (RCTs) of TACE combined with sorafenib, thereby minimizing the potential effects of selection bias inherent in nonrandomized clinical studies. To this end, we performed a meta-analysis of the results of double-blind RCTs that investigated the effects of TACE combined with sorafenib in which TTP or OS were evaluated as primary endpoints and sorafenib-related adverse events were reported as secondary endpoints. Our results suggest that treatment using TACE with sorafenib does not provide significant benefit to HCC patients, compared with that of TACE alone, and that greater consideration should be placed on the adverse events of TACE plus sorafenib.

MATERIALS AND METHODS {#s2}
=====================

Search strategy {#s2_1}
---------------

This report was prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses ([Supplementary Table 1](#SD2){ref-type="supplementary-material"}) guidelines \[[@R18]\]. The Institutional Review Board of our institution deemed our study to be exempt from review because only publicly available data were included in our analysis. We searched for the MEDLINE, EMBASE, EBSCO, Springer, Ovid, and Cochrane Library databases for published reports of RCTs published in English that evaluated the effects of transcatheter hepatic arterial chemoembolization combined with sorafenib on HCC clinical outcomes. The following keywords were used for our search: "transcatheter hepatic arterial chemoembolization", "carcinoma, hepatocellular" \[MeSH\], "chemoembolization, therapeutic" \[MeSH\], "hepatic artery" \[MeSH\], "sorafenib" \[MeSH\], and "randomized controlled trial" \[MeSH\]. We used a date range for our search ending in 2016. The References sections of retrieved articles were also searched manually to identify other relevant RCTs.

Selection criteria {#s2_2}
------------------

The inclusion criteria for our meta-analysis were as follows: RCT; article was published in English; evaluated TACE combined with sorafenib for the treatment of HCC; patients were not suitable candidates for surgical resection; participants were 18 years of age or older; participant selection was not restricted based on sex; primary endpoints included TTP or overall survival (OS); and reported adverse events among patients receiving sorafenib as secondary endpoints. The exclusion criteria were as follows: Allocation not randomized; double blinding not performed; not placebo controlled; included patients with advanced HCC with significant vascular invasion or distant metastases; included patients diagnosed with another severe liver disease; included patients diagnosed with other types of malignant tumors, heart failure, renal failure, or human immunodeficiency virus infection.

Data extraction and quality assessment {#s2_3}
--------------------------------------

The following data were extracted: General information, including article title, authors' names, and journal title; study characteristics, including study design, inclusion and exclusion criteria, study population size and demographic variables, duration of treatment, follow-up duration, and methods of bias prevention; clinical outcome measures (primary endpoints); data regarding loss to follow-up and exit status; adverse events among sorafenib users (secondary endpoints), including fatigue, diarrhea, nausea, hand and foot skin reactions, and/or other types of dermatitis. Quality assessment was performed based on the following criteria: Allocation was sufficiently randomized; blinding for allocation was sufficient; blinding for the intervention was sufficient; and loss to follow-up or exit status were evaluated.

Statistical analysis {#s2_4}
--------------------

The statistical analysis was performed using the Rev.Man 5.2 software provided by Cochrane collaboration network. We used the *I*^2^ statistic to evaluate heterogeneity in the data, with *I*^2^ \> 50% indicating significant heterogeneity. Effect size for the primary endpoints was evaluated based the hazard ratio (HR) and 95% confidence interval (CI) of TTP and OS. Effect size for the secondary endpoints was evaluated as the risk ratio (RR) and 95% CI based on the incidences of the various adverse events reported. Fixed-effects models were used to estimate risk when significant heterogeneity in the data was not detected (*I*^2^ ≤ 50%), whereas random-effects models were used when significant heterogeneity existed (*I*^2^ \> 50%). The overall effect size was evaluated using the *Z* test, with a *P* \< .05 indicating a statistically significant difference between the data for the experimental and control groups. Forest plots were constructed to represent the results of the risk analyses.

RESULTS {#s3}
=======

Study selection {#s3_1}
---------------

As shown in the flow diagram in Figure [1](#F1){ref-type="fig"}, we initially retrieved 57 documents. Forty-nine of these articles were excluded based on the content of the title or abstract, among which 10 were non-RCTs of TACE combined with sorafenib for HCC and 5 were systematic reviews or meta-analyses. Four additional articles were excluded following the evaluation of full-text articles based on the inclusion and exclusion criteria for our study. The remaining 4 RCTs were included in our meta-analysis \[[@R19]--[@R22]\].

![Flow diagram of study selection](oncotarget-08-59601-g001){#F1}

Study characteristics {#s3_2}
---------------------

The characteristics of the selected RCTs are presented in Table [1](#T1){ref-type="table"}. The studies were published between 2011 and 2016. Three of the studies were multicenter RCTs. The study locations included Australia, Austria, Germany, Spain, France, Belgium, Italy, Japan, Republic of Korea, Singapore, Taiwan, China, Canada, and the USA. The study populations included a total of 877 HCC cases who ranged in age from 58 to 73 years. All of the experimental groups were treated with TACE combined with sorafenib, and the control groups received TACE and placebo. The various studies used different methods of randomization for allocation to the experimental and control groups. The dosage of sorafenib was 400 mg twice daily in all of the studies. Blinding and randomization were determined to be adequate in all of the selected RCTs, whereas only one of these studies adequately described allocation concealment \[[@R21]\]. The various adverse events reported included fatigue, diarrhea, nausea, hand and foot skin reaction (HFSR), and other types of dermatological events referred to hereafter as rash. The risks of selection, performance, or detection biases were not quantified in any of the included studies.

###### Study characteristics

  Authors, year           Sorafenib treatment                                   TACE drug                                       Randomized   Blinding   Placebo controlled   Allocation concealed   Study Centers   Countries
  ----------------------- ----------------------------------------------------- ----------------------------------------------- ------------ ---------- -------------------- ---------------------- --------------- -----------
  Kudo et al., 2011       After 1 or 2 TACE sessions                            epirubicin, cisplatin, doxorubicin, mitomycin   yes          Double     yes                  no                     4               1
  Sansonno et al., 2012   30 days after TACE                                    Doxorubicin, mitomycin C                        yes          Double     yes                  yes                    75              2
  Hoffmann et al., 2015   Stopped 3 days before and resumed 3 days after TACE   Carboplatin                                     yes          Double     yes                  no                     85              13
  Lencioni et al., 2016   3−7 days after first TACE                             DEB-TACE, doxorubicin                           yes          Double     yes                  no                     1               1

Clinical outcomes {#s3_3}
-----------------

As shown in Figure [2](#F2){ref-type="fig"}, all of the selected RCTs reported the median and 95% CI of TTP for the experimental and control groups. No selective reporting of clinical outcomes was observed. Significant heterogeneity in the TTP data was not observed (*I*^2^ = 26%). In our comparison of TTP between the experimental and control groups, the total HR of TTP was 0.82 (95% CI: 0.69--0.97; *Z* = 2.29; *p* = 0.02). The results suggest that the risk of disease progression in the experimental groups was lower than that in the control groups. Two of the selected RCTs \[[@R19], [@R22]\] reported the median and 95% CI of OS for the experimental and control groups (Figure [3](#F3){ref-type="fig"}), whereas the other selected RCTs did not report OS data \[[@R20], [@R21]\]. Significant heterogeneity in the OS data was not observed (*I*^2^ = 0%). In our comparison of OS between the experimental and control groups, the total HR of OS was 0.97 (95% CI: 0.72--1.29; *Z* = 0.22; *p* = 0.82). The results suggest that the survival of the patients in the experimental groups was not significantly different than that for patients in the control groups.

![Comparison of time to disease progression\
Forest plots show squares representing the odds ratio for the experimental group compared with the placebo control group. Size of the squares is proportional to the size of the trials, and error bars represent the 95% confidence interval, with the diamond-shaped object representing the pooled estimates within each analysis.](oncotarget-08-59601-g002){#F2}

![Comparison of overall survival\
Forest plots show squares representing the odds ratio for the experimental group compared with the placebo control group. Size of the squares is proportional to the size of the trials, and error bars represent the 95% confidence interval, with the diamond-shaped object representing the pooled estimates within each analysis.](oncotarget-08-59601-g003){#F3}

Adverse events {#s3_4}
--------------

Risk of fatigue {#s3_5}
---------------

Three of the selected RCTs compared the incidence of fatigue between the experimental and control groups \[[@R19]--[@R21]\]. No significant heterogeneity was observed in the fatigue data. The total RR of fatigue was 1.37 (95% CI: 1.04--1.80; *Z* = 2.24; *p* = 0.03; Figure [4A](#F4){ref-type="fig"}). These results suggest that the risk of fatigue among the patients in the experimental group was significantly higher than that among patients in the control groups.

![Comparisons of the risks of adverse events\
Forest plots depict the comparisons of the risks of (**A**) fatigue, (**B**) rash, (**C**) diarrhea, (**D**) nausea in the relevant studies, and the comparisons of hand and foot skin reactions in (**E**) all of the selected studies and (**F**) the studies in which drug-eluting beads were not used. Squares represent the odds ratio for the experimental group compared with the placebo control group, with the size of the square being proportional to the number of cases evaluated. Error bars represent the 95% confidence interval, and the diamond-shaped object representing the pooled estimates within each analysis.](oncotarget-08-59601-g004){#F4}

Risk of rash {#s3_6}
------------

Three of the selected RCTs compared the incidence of rash between the experimental and control groups \[[@R19], [@R21], [@R22]\]. No significant heterogeneity was observed in the rash data (*I*^2^ = 0%). The total RR of rash was 3.49 (95% CI, 2.24--5.43; *Z* = 5.53; *p* \< 0.0001; Figure [4B](#F4){ref-type="fig"}). These results suggest that the risk of rash was significantly greater among the patients in the experimental groups than that in the patients in the control groups.

Risk of diarrhea {#s3_7}
----------------

Four of the selected RCTs compared the incidence of diarrhea between the experimental and control groups. No significant heterogeneity was observed in the rash data (*I*^2^ = 13%). The total RR of diarrhea was 3.35 (95% CI: 2.41--4.66; *Z* = 7.21; *p* \< 0.05; Figure [4C](#F4){ref-type="fig"}). These results suggest that the risk of diarrhea was significantly greater among the patients in the experimental groups than that in the patients in the control groups.

Risk of nausea {#s3_8}
--------------

Three of the selected RCTs compared the incidence of nausea between the experimental and control groups \[[@R19]--[@R21]\]. No significant heterogeneity was observed in the nausea data (*I*^2^ = 0%). The total RR of nausea was 1.05 (95% CI: 0.80--1.38; *Z* = 0.36; *p* = 0.72; Figure [4D](#F4){ref-type="fig"}). These results suggest that the risk of nausea among the patients in the experimental groups was not significantly greater than that in the patients in the control groups.

Risk of HFSR {#s3_9}
------------

All of the selected RCTs reported the incidence of HFSR in the experimental groups. Significant heterogeneity observed in the HFSR data (*I*^2^ = 69%). The total RR of HFSR was 5.93 (95% CI: 2.00--17.53; *Z* = 3.22; *p* = 0.001; Figure [4E](#F4){ref-type="fig"}), which suggested that the risk of HFSR among patients in the experimental groups was significantly greater than that of patients in the control groups. A subgroup analysis was also performed in which the results of the RCT that used drug-eluting beads for TACE \[[@R19]\] were excluded. No significant heterogeneity was observed in the HFSR data used in the subgroup analysis (*I*^2^ = 0%), and the total RR of HFSR was 10.96 (95% CI: 5.54--21.69; *Z* = 6.88; *p* \< 0.05; Figure [4F](#F4){ref-type="fig"}). These results also suggest that the risk of HFSR among patients in the experimental groups was significantly greater than that of patients in the control groups.

DISCUSSION {#s4}
==========

Sorafenib is the only anticancer drug that has been approved for systemic therapy for HCC \[[@R14], [@R23]\]. Studies have shown that sorafenib combined with doxorubicin was more effective for the treatment of intermediate- to late-stage HCC than doxorubicin alone \[[@R24], [@R25]\], and multiple RCTs have evaluated TACE plus sorafenib for late-stage or nonresectable HCC \[[@R19]--[@R22], [@R26]\]. Our meta-analysis of RCTs that investigated the use of TACE with sorafenib or placebo found that, although TACE combined with sorafenib significantly increased TTP (HR: 0.82; 95% CI: 0.69--0.97; *p* = 0.02), TACE with sorafenib did not improve OS significantly (HR: 0.97; 95% CI: 0.72--1.29; *p* = 0.82), compared to TACE plus placebo. Our findings suggest that other factors contribute to poor prognosis in HCC patients despite the delay in disease progression that is experienced in patients receiving TACE plus sorafenib.

Mild to moderate adverse events have been reported in patients treated with sorafenib \[[@R12], [@R24], [@R27]\], including HFSR, rash, fatigue, diarrhea, and nausea. Therefore, we also compared the incidence of these adverse events in patients receiving TACE plus sorafenib to those in patients receiving TACE plus placebo. Our meta-analysis showed that risks of HFSR, rash, fatigue, and diarrhea were significantly greater in the patients treated with TACE plus sorafenib (*p* \< 0.05 for all), compared to those in patients treated with TACE plus placebo, whereas the risk of nausea was statistically similar in the experimental and control groups in the selected RCTs (*p* \> 0.05).

A recent multicenter study conducted in China, Switzerland, and the USA reported that adverse dermatological events related to sorafenib use were associated with survival in intermediate-stage HCC patients treated with TACE and sorafenib in combination \[[@R28]\]. Our results showed that the increases in sorafenib-related HFSR and rash were high with RRs of 5.93 and 3.49, respectively. However, as noted above, median OS did not differ significantly between the TACE plus sorafenib and TACE plus placebo groups in the RCTs included in our meta-analysis. Although our analysis did not directly evaluate the prognostic value of HFSR and rash, our findings seem to be inconsistent with HFSR and rash being positively correlated with survival. Therefore, the prognostic value of sorafenib-related adverse dermatological events might be HCC-stage or time course dependent.

Our findings are, however, subject to certain limitations. We did not assess statistical power for our analysis, but the relatively small number of RCTs included in our meta-analysis represents a potential confounder of our findings. The small number of selected RCTs also precluded the use of funnel plots to assess whether publication bias influenced our findings, but the randomization and double blinding performed in all of the RCTs included in our meta-analysis likely minimized the potential effects of selection, performance, and detection biases. Nonetheless, significant heterogeneity in the TTP or OS data reported was not detected for the RCTs included in our analysis (*I*^2^: 26% and 0%, respectively). In addition, although significant heterogeneity was observed in the HFSR data (*I*^2^ = 69%), no significant heterogeneity was detected for the data used in the subgroup analysis of HFSR, and both the overall and subgroup results showed that the risk of HFSR was greater in the TACE plus sorafenib groups than that in the control groups.

In conclusion, although TACE plus sorafenib increases TTP in patients with HCC, it does not improve OS. Therefore, the increased risk of adverse events in patients receiving TACE plus sorafenib suggests that this combination therapy might not represent an improvement over treatment with TACE alone. The relatively small number of RCTs that met the selection criteria for our meta-analysis demonstrate the need for uniform application of clinical outcome indicators to facilitate future comparisons of studies of TACE plus sorafenib for the treatment of HCC.
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